How to buy Cogent Biosciences stock

Cogent Biosciences, Inc is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 15 staff and has a trailing 12-month revenue of around 0.00.

Cogent Biosciences stock price (NASDAQ: COGT)

Use our graph to track the performance of COGT stocks over time.

Cogent Biosciences shares at a glance

• Key figures

Information last updated 2021-07-25.

52-week range	$6.15 - $14.44
50-day moving average	$7.73
200-day moving average	$8.74
Wall St. target price	$20.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Cogent Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cogent Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cogent Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cogent Biosciences financials

Revenue TTM	$840,000
Gross profit TTM	$-15,967,000
Return on assets TTM	-12.94%
Return on equity TTM	-62.23%
Profit margin	0%
Book value	$3.55
Market capitalisation	$248.9 million

TTM: trailing 12 months

Shorting Cogent Biosciences shares

There are currently 2.0 million Cogent Biosciences shares held short by investors – that's known as Cogent Biosciences's "short interest". This figure is 33.5% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Cogent Biosciences shares can be evaluated.

Cogent Biosciences's "short interest ratio" (SIR)

Cogent Biosciences's "short interest ratio" (SIR) is the quantity of Cogent Biosciences shares currently shorted divided by the average quantity of Cogent Biosciences shares traded daily (recently around 521427.85145889). Cogent Biosciences's SIR currently stands at 3.77. In other words for every 100,000 Cogent Biosciences shares traded daily on the market, roughly 3770 shares are currently held short.

However Cogent Biosciences's short interest can also be evaluated against the total number of Cogent Biosciences shares, or, against the total number of tradable Cogent Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cogent Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cogent Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0616% of the tradable shares (for every 100,000 tradable Cogent Biosciences shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cogent Biosciences.

Find out more about how you can short Cogent Biosciences stock.

Cogent Biosciences share dividends

We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.

Have Cogent Biosciences's shares ever split?

Cogent Biosciences's shares were split on a 1:4 basis on 8 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.

Cogent Biosciences overview

Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc.

Frequently asked questions

What percentage of Cogent Biosciences is owned by insiders or institutions?
Currently 0.558% of Cogent Biosciences shares are held by insiders and 105.33% by institutions. How many people work for Cogent Biosciences?
Latest data suggests 15 work at Cogent Biosciences. When does the fiscal year end for Cogent Biosciences?
Cogent Biosciences's fiscal year ends in December. Where is Cogent Biosciences based?
Cogent Biosciences's address is: 200 Cambridge Park Drive, Cambridge, MA, United States, 02140 What is Cogent Biosciences's ISIN number?
Cogent Biosciences's international securities identification number is: US19240Q2012